Neogap granted Chinese patent for innovative method of MS treatment and diagnosis
Neogap Therapeutics, a Swedish biotechnology company specialising in the development of personalised immunotherapy, has been granted a patent in China for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent, which complements a previously granted patent in Australia, strengthens Neogap's global presence in the field, the company's strategic intellectual property portfolio, and its ongoing research into autoimmune diseases such as MS.
The patent covers a tolerogenic treatment method for multiple sclerosis (MS) using specially designed molecules to modulate the immune system's response by training it to tolerate rather than attack the body's own cells. Correcting these misguided immune responses is crucial for treating MS. The patent will remain valid until 2038.
By integrating this method with its EpiTCer® technology, Neogap can develop improved treatment and diagnostic approaches for MS. This combination of a patented method and advanced technology unlocks new possibilities for developing innovative and targeted treatment strategies for the disease.
"With the newly granted patent in China, we are not only strengthening our international position in biotechnology but also expanding the applications of our EpiTCer® technology," says Samuel Svensson, CEO of Neogap Therapeutics. "While our primary focus remains on developing cancer treatments, this patent also opens new avenues for the treatment and diagnosis of MS. It demonstrates our ability to successfully expand our research areas to include other serious health conditions, contributing to our capacity to offer even more effective solutions for combating both cancer and autoimmune diseases."
Beyond its application in MS treatment, the patent also incorporates methods for diagnosing MS, thus improving the prospects for early detection and treatment of the disease. The inventors are Associate Professor Hans Grönlund, CSO and founder of Neogap, and Mattias Bronge, MD, PhD.
About EpiTCer®
EpiTCer® is a patented method that enables the detection and analysis of antigen-specific, autoreactive T-cells. The technology is being utilised in the company's ongoing Phase I/II clinical trial of personalised immunotherapy for colorectal cancer. Additionally, EpiTCer® holds the potential to be used in other diseases and conditions where the immune system is either overreactive or insufficiently sensitive, such as infectious diseases, autoimmune diseases, and allergies.
For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94
About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap on LinkedIn.
Tags:
